Response to PARPi has initially been observed in ovarian cancer patients with alterations in the genes BRCA1 and BRCA2,17, 18 but later studies reported that clinical response was also observed in patients with BRCA1/2 wildtype status.19, 20. The gene discussed is BRCA1; the disease is ovarian cancer.